Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class I · High risk

Eye Wash

Non-Sterility: Direct evidence of contamination for 2 lots based on FDA samples.

Terminated Sterility / contamination United Exchange Corporation NDC 0904-6491-20 D-0496-2017
Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-308-10 D-0214-2017
Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-307-10 D-0213-2017
Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-309-10 D-0212-2017
Class II · Moderate risk

Phenylephrine HCI Injection

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.

Terminated Sterility / contamination Sandoz Inc NDC 66758-016-03 D-1514-2016
Class II · Moderate risk

Ephedrine Sulfate Injection

Lack of Assurance of Sterility: a recent FDA inspection at the manufacturing firm raised concerns that product sterility may be compromised.

Terminated Sterility / contamination Sandoz Inc NDC 66758-008-01 D-1513-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-887-32 D-1490-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-909-32 D-1489-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-832-25 D-1488-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-898-32 D-1487-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-815-25 D-1486-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 60687-154-25 D-1485-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-943-25 D-1484-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 60687-133-25 D-1483-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-936-25 D-1482-2016
Class II · Moderate risk

Dextroamphetamine Saccharate

Unit Dose Mispackaging; blister cavities may contain more than one tablet /capsule

Terminated Labeling / mix-up Amerisource Health Services NDC 68084-874-25 D-1481-2016
Class II · Moderate risk

Transderm Scop

Defective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.

Terminated Packaging defect Sandoz Inc D-0133-2017
Class III · Low risk

Selegiline HCL Tablets USP 5mg

Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.

Terminated Dissolution failure Stason Pharmaceuticals, Inc. NDC 51862-146-06 D-1479-2016
Class III · Low risk

Lamotrigine Tablets

Tablets/Capsules Imprinted With Wrong ID: incorrect imprint debossed on the tablets.

Terminated Labeling / mix-up Unichem Pharmaceuticals Usa Inc NDC 29300-113-05 D-1519-2016

Recalls by year